TrialBMC medicine2022

Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.

Zhengbo Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.